Lincoln Pharmaceuticals (NSE:LINCOLN) Moat Score: 0/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:LINCOLN Lincoln Pharmaceuticals Ltd NSE:LINCOLN
82 GF Score
Price ₹606.95
GF Value ₹711.96
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lincoln Pharmaceuticals Moat Score?

Lincoln Pharmaceuticals has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Lincoln Pharmaceuticals has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Lincoln Pharmaceuticals might have No Moat - No discernible moat.

Lincoln Pharmaceuticals  (NSE:LINCOLN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Lincoln Pharmaceuticals Moat Score Related Terms

NSE:LINCOLN
82GF Score
Lincoln Pharmaceuticals Ltd NSE:LINCOLN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued. The current stock price of ₹606.95 is trading 14.7% below its estimated GF Value™ of ₹711.96. GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NSE:LINCOLN:

  • Moat Score: 0
  • GF Value™: ₹711.96 vs. price of ₹606.95 (14.7% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lincoln Pharmaceuticals Business Description

Other Exchanges 531633:India
Address Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
82GF Score

Get the complete analysis for NSE:LINCOLN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹606.95
Price
₹711.96
GF Value